Chronic hepatitis C virus disease: An evaluation of procedures for diagnosis and treatment

Netherlands Journal of Medicine

Volumn 51, Issue 6, 1997, Pages 213-224

  Stadhouders, P H G M ^a   Cooreman, M P ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic HCV infection; HCV antiviral therapy; Hepatitis C virus; Predictive factors

Indexed keywords

INTERFERON;

CHRONICITY; DISEASE SEVERITY; EVALUATION AND FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PROGNOSIS; REVIEW; VIRUS LOAD;

ACUTE DISEASE; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; NETHERLANDS; PROGNOSIS; RISK FACTORS;

EID: 0031473399     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(97)00045-4     Document Type: Review

References (111)

1. Willems M, Moshage H, Fevery J, Yap SH. Hepatitis C. Neth J Med 1992;41:36-43.
2. Houghton M, Weiner A, Han J, Kuo G, Choo Q. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991;14:381-388.
3. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21:570-583.
4. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-1324.
5. Lau JYN, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Ann Intern Med 1996; 124:868-876.
6. Alter MJ, Mast BE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-455.
7. Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995;332:1509-1511.
8. Dorozynski A. Half a million French are infected with hepatitis C virus. Br Med J 1995;311:1187-1188.
9. Donahue DIG, Muñoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-373.
10. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. J Am Med Assoc 1990;264:2231-2235
11. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. J Am Med Assoc 1989;262:1201-1205.
12. Estaban JI, Gomez J, Martell M, et al. Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med 1996;334:555-560.
13. Neal KR, Jones DA, Killey D, James V. Risk factors for hepatitis C virus infection: a case-control study of blood donors in the Trent Region (UK). Epidemiol Infect 1994;112:595-601.
14. Fingerhood MI, Jasinski DR, Sullivan JT. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med 1993;153:2025-2030.
15. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345:1209-1211.
16. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995;345:289-291.
17. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994;330:744-750.
18. Zuckerman J, Clewley G, Griffiths P, Cockcroft A. Prevalence of hepatitis C antibodies in clinical health-care workers. Lancet 1994;343:1618-1620.
19. Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Prevalence of antibodies against hepatitis C virus infection among health care workers in Stockholm. Scand J Gastroenterol 1994;29:360-362.
20. Sjogren MH. Serologic diagnosis of viral hepatitis. Gastroenterol Clin North Am 1994;23:457-477.
21. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911.
22. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
23. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
24. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis Band C- viral infection in Japan. Hepatology 1995;22:1027-1033.
25. Sallie R, Di Bisceglie AM. Viral hepatitis and hepato-cellular carcinoma. Gastroenterol Clin North Am 1994;23:567-579.
26. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotype 1 and 2 hepatitis C virus. Hepatology 1996;23:695-699.
27. Misiani RM, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992;117:573-577.
28. Pawlotsky J-M, Dhumeaux D, Bagot M. Hepatitis C virus in dermatology. Arch Dermatol 1995;131:1185-1193.
29. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995;123:615-620.
30. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992;339:321-323.
31. Tran A, Quaranta J-F, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993;18:253-257.
32. DeCastro M, Sanchez J, Herrera JF, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993;17:551-557.
33. Navas S, Bosch O, Castillo I, Marriott E, Carreno V. Porphyria cutanea tarda and hepatitis C and B viruses infection: a retrospective study. Hepatology 1995;21:279-284.
34. Stolzel U, Kostler E, Koszka C, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995;21:1500-1503.
35. Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995;70:559-564.
36. Agnello V, Romain PL. Mixed cryoglobulinemia secondary to hepatitis C virus infection. Rheum Dis Clin North Am 1996;22:1-19.
37. Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994;88:392-394.
38. Pioltelli P, Zehender G, Monti G, Monteverde A, Galli M. HCV and non-Hodgkin lymphoma. Lancet 1996;347:624-625.
39. Thalen DJ, Raemaekers J, Galama J, Cooreman MP. Absence of hepatitis C virus infection in non-Hodgkin's lymphoma. Br J Haematol 1997; in press.
40. Fong T-L, Kanel GC, Conrad A, Valinluck B, Charboneau F, Adkins RH. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994;19:554-557.
41. Oshita M, Hayashi N, Kasahara A, et al, Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994;20:1115-1120.
42. Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis, a prospective study. Cancer 1994; 74:2442-2448.
43. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-655.
44. Tsai SL, Liaw YF, Yen CT, Chu CM, Kuo GC. Cellular immune response in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus. Hepatology 1995;21:908-912.
45. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patients' survival. Hepatology 1994;20:1152-1155.
46. Telfer PT, Brown D, Devereux H, Lee CA, DuSheiko GM. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Br J Haematol 1994;88:397-399.
47. Chambost H, Gerolami V, Halfon P, et al. Persistent hepatitis C virus RNA replication in haemophiliacs: role of co-infection with human immunodeficiency virus. Br J Haematol 1994;91:703-707.
48. Berger A, von Depka-Prondzinski M, Doerr HW, Rabenau H, Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV co-infection. J Med Virol 1996;48:339-343.
49. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci 1996;41:1265-1275.
50. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21:613-619.
51. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou J-P. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992;116:51-53.
52. García-Buey L, García-Monzón C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during Interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-1777.
53. Cooreman MP, Schoondermark-van de Ven EME. Hepatitis C virus: Biological and clinical consequences of genetic heterogeneity. Scand J Gastroenterol 1996;31 suppl 218:106-115.
54. Meyer zum Büschenfelde KH, Lohse AW, Gerken G, et al. The role of autoimmunity in hepatitis C infection. J Hepatol 1995;22(S1):93-96.
55. Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of Interferon alpha therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995;22:1374-1378.
56. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995;15:70-81.
57. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
58. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
59. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995;22:418-425.
60. Tedeschi V, Seeff LB. Diagnostic tests for hepatitis C: where are we now?. Ann Intern Med 1995;123:383-385.
61. Rubin R, Falestiny M, Malet P. Chronic hepatitis C: advances in diagnostic testing and therapy. Arch Intern Med 1994;154:387-392.
62. Silini E, Bono F, Cividini A, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285-290.
63. Vrielink H, Zaaijer HL, Reesink HW, van der Poel CL, Cuypers HT, Lelie PN. Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs. Vox Sang 1995;69:14-17.
64. Courouce AM, Janot C. Recombinant immunoblot assay first and second generations on 732 blood donors reactive for antibodies to hepatitis C virus by ELISA. Vox Sang 1991;61:177-180.
65. Gretch DR, Corazon dela Rosa MT, Carithers RL, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications, Ann Intern Med 1995;123:321-329.
66. Alberti A. Interferon therapy of acute hepatitis C. Viral Hepatitis 1995;1:37-45.
67. Cammà C, Almasio P, Craxì A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996; 41:1248-1255.
68. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of Interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778-789.
69. Davis GL, Lau JY, Lim HL. Therapy for chronic hepatitis C. Gastroenterol Clin North Am 1994;23:603-613.
70. Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996;23:909-916.
71. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995;21:1003-1010.
72. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon, a preliminary report. N Engl J Med 1986;315:1575-1578.
73. Hoofnagle JH, Lau D. Chronic viral hepatitis - benefits of current therapies. N Engl J Med 1996;334:1470-1471.
74. Nishiguchi S, Kuroki T, Nakatani S, et al, Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
75. Reichard O, Glaumann H, Fryden A, et al. Two-year bio-chemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alpha-2b treatment. Hepatology 1995;21:918-922.
76. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1994;330:143.
77. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994;19:1088-1094.
78. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993;104:877-883.
79. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alpha therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-1354.
80. Jouët P, Roudot-Thoraval F, Dhumeaux D, et al. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106:686-690.
81. Sieck JO, Ellis ME, Alfurayh O, et al. Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study. J Hepatol 1994;19:418-423.
82. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994;21:1-3.
83. Olynyk JK, Reddy KR, Di Bisceglie AM, et al. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Gastroenterology 1995;108:1104-1109.
84. Orito E, Mizokami M, Suzuki K, et al. Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995;46:109-115.
85. Colloredo G, Bellati G, Ricci A, et al. HCV-RNA as a predictor of relapse after interferon therapy for chronic hepatitis C. Hepatology 1996;24:156A.
86. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987;147:1577-1580.
87. Dusheiko CM, Khakoo S, Soni P, Grellier L. A rational approach to the management of hepatitis C infection. Br Med J 1996;312:357-364.
88. Perrillo RP, Mason AL. Therapy for hepatitis B virus infection. Gastroenterol Clin North Am 1994;23:581-601.
89. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-706.
90. Reichard O, Foberg U, Frydén A, et al. High sustained response rate and clearance of viraemia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks. Hepatology 1994;19:280-285.
91. Marcellin P, Pouteau M, Martinot-Peignoux M, et al. Lack of benefit of escalating dosage of interferon alpha in patients with chronic hepatitis C. Gastroenterology 1995; 109:156-165.
92. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-1462.
93. Bennett WG, Inoue Y, Beck JR, Pauker SG, Davis GL. Justification of a single 6-month course of interferon (IFN) for histologically mild chronic hepatitis C. Hepatology 1995;22:290A.
94. Roffi L, Mels GC, Antonelli G, et al. Breakthrough during recombinant interferon alpha therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995;21:645-649.
95. Booth JCL, Brown JL, Thomas HC. The management of chronic hepatitis C virus infection. Gut 1995;37:449-454.
96. Reicherd O, Andersson J, Schvarcz R, Weiland O. Ribavarin treatment for chronic hepatitis C. Lancet 1991;337:1058-1061.
97. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavarin as therapy for chronic hepatitis C. Ann Intern Med 1995;123:897-903.
98. Mutchnick MG, Ehrinpreis MN, Kinzie JL, Peleman RR. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res 1994;24:245-257.
99. Kakumu S, Yoshioka K, Wakiti T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavarin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993;105:507-512.
100. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol 1995;23 suppl 2:8-12.
101. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
102. Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur J Gastroenterol Hepatol 1995;7:151-154.
103. Angelico M, Gandin C, Pescarmona E, et al. Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995;90:263-269.
104. Boucher E, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995;21:322-327.
105. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988.
106. Beloqui O, Prieto J, Suarez M, et al, N-acetyl cysteine enhances the response to interferon-α in chronic hepatitis C: a pilot study. J Interferon Res 1993;13:279-282.
107. Pappas SC, Hoofnagle JH, Young N, et al. Treatment of chronic non-A, non-B hepatitis with acyclovir: pilot study. J Med Virol 1985;15:1-9.
108. Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-355.
109. Konig V, Bauditz J, Lobeck H, et al. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. Hepatology 1992;16:1137-1143.
110. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
111. Greenson JK, Svoboda-Newman SM, Merion RM, Frank TS. Histologic progression of recurrent hepatitis C in liver transplant allografts. Am J Surg Pathol 1996;20:731-738.